Voyageur Pharma appoints Mueller director of chemistry

Executive Summary

• Voyageur Pharmaceuticals acquired 100% ownership of Dr. Brian Mueller’s proprietary "Mueller Process" iodine extraction technology and appointed Dr. Mueller as Director of Chemistry.
• The acquisition includes an initial cash payment and a running royalty on net sales, aiming to enhance cost efficiency, supply-chain security, and operational flexibility for iodine projects.
• Initial bench-scale testing of brine from the Anadarko and West Texas basins showed a 90% yield to technical grade iodine and the potential for direct production of iodine drugs, bypassing traditional flake processes.
• The company also announced the termination of its collaboration with Altillion Inc.

Key Details

• Technology Acquisition: Voyageur acquired intellectual property rights to the "Mueller Process," a proprietary iodine-extraction technology developed by Dr. Brian Mueller.
• Consideration: The transaction involved a lump sum initial cash payment and a running royalty on net sales of iodine products; it is an arm's-length transaction.
• Personnel: Dr. Brian Mueller, PhD, was appointed as Director of Chemistry, effective immediately.
• Testing Results (Bench Scale):
  • 90% yield from incoming brine to technical grade iodine (85% pure).
  • Capability to convert to 99.5% pure iodine.
  • Environmentally friendly closed process with no volatile organic compounds or hazardous emissions.
  • Output brine is "clean brine" suitable for industrial use, hydraulic fracturing, desalination, or further mineral extraction.
  • Note: Testing completed by Dr. Mueller; third-party evaluation expected in 2026; results not independently verified.
• Strategic Applications:
  • Immediate focus on iodine extraction in the Anadarko basin.
  • Potential to bypass the flake process entirely, directly creating iodine drugs via a proprietary streamlined API process.
  • Potential for elemental mineral extraction (lithium, iodine, bromine, boron, magnesium, potassium, sodium) from the ULI claim block in the Paradox basin, Utah.
• Patent Status: Provisional patent applications were filed in 2025; full utility patent applications are expected to be submitted in 2026.
• Market Context: Global contrast media market estimated at $6.77 billion (2024), projected to reach $13.86 billion by 2033 (CAGR 8.3%). North American market share estimated at 39.07% ($2.65 billion/year).
• Collaboration Termination: Voyageur delivered notice to Altillion Inc. to terminate their collaboration, previously announced on June 23, 2025.

Notable Quotes

• "With provisional patent applications for the intellectual property acquired by Voyageur filed in 2025, we are on track to submit full utility patent applications in 2026. Our immediate focus is on iodine extraction in the Anadarko basin, where we believe this technology will allow us to produce iodine flake efficiently." — Brent Willis, CEO and President
• "More importantly, it may enable us to bypass the flake process entirely, directly creating iodine drugs through our proprietary streamlined API [active pharmaceutical ingredients] process. This potential capability not only enhances our potential ability to produce high-quality, cost-effective iodine contrast agent, but is expected to allow Voyageur to achieve one of the lowest cost structures in the multibillion-dollar iodine contrast drug industry." — Brent Willis, CEO and President